Segment Information - Significant expense categories (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 13, 2025 |
|
| Segment Information | |||||
| Upfront cash payment | $ 12,000 | ||||
| Research and development expenses | |||||
| Total R&D | $ 7,425 | $ 24,091 | $ 14,259 | $ 31,987 | |
| General and administrative expenses | |||||
| Total G&A | 2,592 | 3,201 | 5,863 | 6,927 | |
| Single reporting segment | |||||
| Segment Information | |||||
| Upfront cash payment | 17,000 | 17,000 | |||
| Research and development expenses | |||||
| Employee costs | 1,536 | 2,341 | 3,575 | 5,271 | |
| Clinical product candidates | 4,250 | 2,569 | 7,290 | 5,604 | |
| Nonclincal product candidates | 746 | 981 | 1,604 | 1,646 | |
| Depreciation and amortization | 265 | 618 | 541 | 1,254 | |
| Other R&D | 628 | 17,582 | 1,249 | 18,212 | |
| Total R&D | 7,425 | 24,091 | 14,259 | 31,987 | |
| General and administrative expenses | |||||
| Employee costs | 877 | 1,374 | 2,400 | 3,451 | |
| Professional services | 1,160 | 1,266 | 2,273 | 2,346 | |
| Insurance | 233 | 243 | 455 | 505 | |
| Other G&A | 322 | 318 | 735 | 625 | |
| Total G&A | $ 2,592 | $ 3,201 | $ 5,863 | $ 6,927 | |
| X | ||||||||||
- Definition The expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, relating to employee costs. No definition available.
|
| X | ||||||||||
- Definition The expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, relating to insurance services. No definition available.
|
| X | ||||||||||
- Definition The expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, relating to professional services. No definition available.
|
| X | ||||||||||
- Definition The amount of cash outflow pertaining to upfront payment under the licensing agreements. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development, relating to clinical product candidates. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development, relating to depreciation. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development, relating to employee costs. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development, relating to non-clinical product candidates. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|